The use of historical controls in rare disease trials, using existing medical history information on a group of similar patients, rather than using a traditional placebo group, is gaining industry and regulatory support. Will Maier discusses challenges and opportunities in the Autumn 2019 issue of Pharmafile.
Read the articleRare and orphan diseases insights
ICON's Rare and Orphan Diseases team provides analysis including whitepapers, blogs and contributions to media and industry conversations relating to all aspects of rare and orphan diseases in clinical trials.
Read moreRelated Information
Blog
The Rare Disease Revolution
Whitepaper
Post-Approval Studies for Rare Disease Treatments and Orphan Drugs | SpringerLink
Media Article
Rare Disease Trials Q&A
Whitepaper
Reimbursement of Orphan Drugs - Part 1: Identifying Evidence
Case Study
Not My Rare Disease: The Importance of Understanding the Patient Experience
Whitepaper
Reimbursement of Orphan Drugs - Part 2: Obtaining Evidence
Blog
How to Accelerate Drug Development for Patients with Rare Diseases
Webinar
The Rare Disease Revolution
Whitepaper
Reimbursement of Orphan Drugs - Part 3: Communicating Evidence
Video
Rare Disease Day 2019
Blog